AC Immune (ACIU) Cash from Investing Activities (2015 - 2025)

AC Immune (ACIU) has reported Cash from Investing Activities for 11 consecutive years, with $20.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash from Investing Activities rose 558.45% year-over-year to $20.0 million; the TTM figure through Dec 2025 stood at $78.0 million (up 166.34% YoY), while the FY2025 annual figure was $76.6 million, up 163.77% from the prior year.
• Cash from Investing Activities declined to $20.0 million in Q4 2025 per ACIU's latest filing, from $25.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $46.3 million in Q1 2023 and bottomed at -$83.8 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$69004.6 across 5 years, with a median of -$561917.7 in 2021.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 8013.88% — and 2024, when it tumbled 1362.29%.
• AC Immune's Cash from Investing Activities stood at -$23.6 million in 2021, then jumped by 121.85% to $5.1 million in 2022, then jumped by 409.85% to $26.2 million in 2023, then tumbled by 116.64% to -$4.4 million in 2024, then jumped by 558.45% to $20.0 million in 2025.
• Business Quant data shows ACIU's Cash from Investing Activities at $20.0 million in Q4 2025, $25.8 million in Q3 2025, and $28.8 million in Q2 2025.